Michael G. Shlipak; Ronit Katz; Mark J. Sarnak; Linda F. Fried; Anne B. Newman; Catherine Stehman-Breen; Stephen L. Seliger; Brian Kestenbaum; Bruce Psaty; Russell P. Tracy; David S. Siscovick
In this longitudinal study involving 4663 elderly persons without known kidney disease (estimated glomerular filtration rate ≥ 60 mL/min per 1.73 m2), increasing cystatin C concentration was associated with increased risks for death, stroke, myocardial infarction, heart failure, and progression to chronic kidney disease. These associations were much stronger for cystatin C than for creatinine.
Ann Intern Med. 2006;145(4):237-246. doi:10.7326/0003-4819-145-4-200608150-00003
Andrew S. Levey; Josef Coresh; Tom Greene; Lesley A. Stevens; Yaping (Lucy) Zhang; Stephen Hendriksen; John W. Kusek; Frederick Van Lente;
Using standardized creatinine assays, the authors remeasured serum creatinine levels in 1628 patients whose glomerular filtration rate (GFR) had been measured by urinary clearance of 125I-isothalamate. They used these data to derive new equations for estimating GFR from age, sex, ethnicity, and serum creatinine and then measured their accuracy. The equations were inaccurate only when kidney function was near-normal.
Ann Intern Med. 2006;145(4):247-254. doi:10.7326/0003-4819-145-4-200608150-00004
André G. Uitterlinden; Stuart H. Ralston; Maria Luisa Brandi; Alisoun H. Carey; Daniel Grinberg; Bente L. Langdahl; Paul Lips; Roman Lorenc; Barbara Obermayer-Pietsch; Jonathan Reeve; David M. Reid; Antonietta Amedei; Amelia Bassiti; Mariona Bustamante; Lise Bjerre Husted; Adolfo Diez-Perez; Harald Dobnig; Alison M. Dunning; Anna Enjuanes; Astrid Fahrleitner-Pammer; Yue Fang; Elzbieta Karczmarewicz; Marcin Kruk; Johannes P.T.M. van Leeuwen; Carmelo Mavilia; Joyce B.J. van Meurs; Jon Mangion; Fiona E.A. McGuigan; Huibert A.P. Pols; Wilfried Renner; Fernando Rivadeneira; Natasja M. van Schoor; Serena Scollen; Rachael E. Sherlock; John P.A. Ioannidis; ; ; ; ; ; ;
This multicenter, prospective study involving 26 242 participants examined associations between vitamin D receptor polymorphisms (Cdx2 promoter, FokI, BsmI, ApaI, and TaqI), bone mineral density (BMD), and fractures. These polymorphisms were not associated with BMD at the lumbar spine or femoral neck. Only the Cdx2 A-allele was associated with a small reduction in risk for vertebral fracture.
Ann Intern Med. 2006;145(4):255-264. doi:10.7326/0003-4819-145-4-200608150-00005
Laura A. Petersen; LeChauncy D. Woodard; Tracy Urech; Christina Daw; Supicha Sookanan
This paper reviewed empirical studies that assessed the relationship between explicit financial incentives and the provision of high-quality health care. Thirteen of 17 studies examined the effect of incentives on process-of-care quality measures. Five of the 6 studies of physician-level financial incentives and 7 of the 9 studies of provider group–level financial incentives found partial or positive associations with measures of quality. One of the 2 studies of incentives at the payment-system level found a positive effect on access to care. In all, 4 studies suggested unintended effects of incentives.
Ann Intern Med. 2006;145(4):265-272. doi:10.7326/0003-4819-145-4-200608150-00006
Jane E. Sisk; Paul L. Hebert; Carol R. Horowitz; Mary Ann McLaughlin; Jason J. Wang; Mark R. Chassin
This 12-month trial of assistance with managing systolic-dysfunction heart failure randomly assigned 406 ethnically diverse adults from Harlem, New York, to usual care or nurse management. Nurse management patients received counseling about sodium intake, fluid buildup, medication adherence, and self-management of symptoms. Nurses also regularly called patients and served as a bridge between patients and physicians. Compared with patients who received usual care, nurse management patients had fewer hospitalizations and better functioning.
Ann Intern Med. 2006;145(4):273-283. doi:10.7326/0003-4819-145-4-200608150-00007
Michael A. Steinman; Lisa A. Bero; Mary-Margaret Chren; C. Seth Landefeld
The authors used documents that became public through a court case to describe a manufacturer's methods to promote off-label uses of gabapentin. The manufacturer extensively used activities usually considered free of promotional intent, including continuing medical education and research, to promote gabapentin. Academic physicians played a large role in these activities. Academic medical centers must maintain a clearer separation between commercial activity and their mission of science and patient care.
Ann Intern Med. 2006;145(4):284-293. doi:10.7326/0003-4819-145-4-200608150-00008
Norton J. Greenberger; Prateek Sharma
This year's Update in Gastroenterology and Hepatology discusses Barrett esophagus, recurrent ulcer bleeding, colorectal cancer screening and prevention, traveler's diarrhea and Clostridium difficile–associated diarrhea, nonalcoholic fatty liver disease, smoking and chronic pancreatitis, and surgical treatment for obesity.
Ann Intern Med. 2006;145(4):294-298. doi:10.7326/0003-4819-145-4-200608150-00009
Josef Coresh; Brad Astor
In this issue, Shlipak and colleagues show that 2 markers of decreased kidney function, estimated glomerular filtration rate and cystatin C, are strong risk factors for noncardiovascular death as well as cardiovascular death and incidence. The most urgent next step is to evaluate these markers in combination with data on albuminuria.
Ann Intern Med. 2006;145(4):299-301. doi:10.7326/0003-4819-145-4-200608150-00010
Jennifer S. Lee; Margaret A. Tucker
In the next quarter-century, the number of individuals affected by osteoporosis and related fractures will double. Understanding the pathogenesis of osteoporosis will require characterizing the interplay among multiple gene variants, gene products, environmental mediators, and bone. This is an essential step toward discovery of drugs that target the causative biological mechanism. In this issue, Uitterlinden and colleagues provide an excellent example that multicenter collaborative studies are crucial to efficiently and correctly identifying genes involved in osteoporosis and other complex diseases.
Ann Intern Med. 2006;145(4):302-304. doi:10.7326/0003-4819-145-4-200608150-00012
Jane E. Henney
The article by Steinman and colleagues in this issue on the marketing of gabapentin guides the author's discussion of off-label uses of drugs, the changing regulatory power of the U.S. Food and Drug Administration, the role of industry, and the involvement of the medical profession in promoting off-label use, as well as clinicians' fundamental obligation to protect the best interests of their patients.
Ann Intern Med. 2006;145(4):305-307. doi:10.7326/0003-4819-145-4-200608150-00013
Anyone becoming a doctor will at some point be told by a reluctant patient, “You're not practicing on me,” or “I'm not having a medical student or a resident learning on me.” Usually, what ensues is a cowardly exodus of the trainee from the patient's room and a quick plea to the attending physician.
Ann Intern Med. 2006;145(4):308-309. doi:10.7326/0003-4819-145-4-200608150-00014
Ann Intern Med. 2006;145(4):310. doi:10.7326/0003-4819-145-4-200608150-00015
Ann Intern Med. 2006;145(4):310. doi:10.7326/0003-4819-145-4-200608150-00016
Ann Intern Med. 2006;145(4):310-312. doi:10.7326/0003-4819-145-4-200608150-00017
Ann Intern Med. 2006;145(4):312. doi:10.7326/0003-4819-145-4-200608150-00018
Jennifer Fisher Wilson
Ann Intern Med. 2006;145(4):313-316. doi:10.7326/0003-4819-145-4-200608150-00019
George N. Braman
Ann Intern Med. 2006;145(4):301. doi:10.7326/0003-4819-145-4-200608150-00011
Ann Intern Med. 2006;145(4):I-28. doi:10.7326/0003-4819-145-4-200608150-00001
Ann Intern Med. 2006;145(4):I-22. doi:10.7326/0003-4819-145-4-200608150-00002
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use